Literature DB >> 23773408

Predictors of PEG dependence after IMRT±chemotherapy for oropharyngeal cancer.

Giuseppe Sanguineti1, Nikhil Rao, Brandon Gunn, Francesco Ricchetti, Claudio Fiorino.   

Abstract

PURPOSE: To prospectively assess predictors of PEG dependence after IMRT with/without concomitant chemotherapy (CHT). METHODS AND MATERIALS: One-hundred-seventy-one patients were considered (exclusive RT: 58, RT+CHT: 113; 159/171 treated at a median dose of 70 Gy, 2 Gy/fr). Patients treated with RT+CHT underwent prophylactic PEG insertion; PEG was as needed for the others. A number of clinical factors and dose-volume information concerning oral mucosa (OM), constrictors, masticatory muscles, larynx, esophagus and parotids were available. The 25th/10th percentiles of the duration of PEG dependence were our end-points (respectively 3.3 and 7 months, PEG3/PEG7). Logistic uni and multi-variate (MVA) analyses were performed.
RESULTS: Concerning PEG3, the independent predictors at MVA were: CHT/PEG policy (OR: 6.8, p=0.001), V9.5G_OMGy/week (OR: 1.017, p=0.01), larynx V50 (OR: 1.018, p=0.01) and superior constrictor (SC) D_mean (OR: 1.002, p=0.005); the predictive value of the model (AUC) was 0.818 (95% CI: 0.751-0.873). The independent predictors of PEG7 were: larynx V50 (OR: 1.042, p=0.0005) and SC D_mean (OR: 1.003, p=0.02), symptoms at diagnosis (yes vs no, OR: 3.6, p=0.08) and sex (male vs female, OR: 0.25, p=0.07); AUC was 0.897 (95% CI: 0.841-0.939).
CONCLUSIONS: OM V9.5 Gy/week and CHT/PEG_policy modulate the risk of early PEG dependence. For longer PEG dependence, larynx V50 (or D_mean) and SC D_mean are highly predictive, suggesting that the fibrosis of constrictors and larynx is the main cause.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Dysphagia; IMRT; PEG tube; Predictive models

Mesh:

Year:  2013        PMID: 23773408     DOI: 10.1016/j.radonc.2013.05.021

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  18 in total

1.  Organ sparing and clinical outcome with step-and-shoot IMRT for head and neck cancer: a mono-institutional experience.

Authors:  Rosario Mazzola; Giuseppe Ferrera; Filippo Alongi; Mariella Mannino; Boris Abbate; Teresa Cucchiara; Giuseppina Iacoviello; Francesco Sciumè; Gioacchino Di Paola; Manuela Federico; Livio Blasi; Antonio Lo Casto; Roberto Lagalla; Domenico Messana
Journal:  Radiol Med       Date:  2015-02-07       Impact factor: 3.469

2.  Predictive Factors for Prophylactic Percutaneous Endoscopic Gastrostomy (PEG) Tube Placement and Use in Head and Neck Patients Following Intensity-Modulated Radiation Therapy (IMRT) Treatment: Concordance, Discrepancies, and the Role of Gabapentin.

Authors:  Wuyang Yang; Todd R McNutt; Sara A Dudley; Rachit Kumar; Heather M Starmer; Christine G Gourin; Joseph A Moore; Kimberly Evans; Mysha Allen; Nishant Agrawal; Jeremy D Richmon; Christine H Chung; Harry Quon
Journal:  Dysphagia       Date:  2016-01-11       Impact factor: 3.438

3.  Beyond mean pharyngeal constrictor dose for beam path toxicity in non-target swallowing muscles: Dose-volume correlates of chronic radiation-associated dysphagia (RAD) after oropharyngeal intensity modulated radiotherapy.

Authors: 
Journal:  Radiother Oncol       Date:  2016-02-17       Impact factor: 6.280

Review 4.  The effect of prophylactic percutaneous endoscopic gastrostomy (PEG) tube placement on swallowing and swallow-related outcomes in patients undergoing radiotherapy for head and neck cancer: a systematic review.

Authors:  Stephanie M Shaw; Heather Flowers; Brian O'Sullivan; Andrew Hope; Louis W C Liu; Rosemary Martino
Journal:  Dysphagia       Date:  2015-03-04       Impact factor: 3.438

5.  Squamous cell carcinoma of the lip: depth of invasion, local recurrence and regional metastases. Experience of a rural multidisciplinary head and neck unit.

Authors:  A Pastuszek; M Hanson; R Grigg
Journal:  J Laryngol Otol       Date:  2015-08-25       Impact factor: 1.469

6.  Cachexia induces head and neck changes in locally advanced oropharyngeal carcinoma during definitive cisplatin and image-guided volumetric-modulated arc radiation therapy.

Authors:  R Mazzola; F Ricchetti; A Fiorentino; G Di Paola; S Fersino; N Giaj Levra; R Ruggieri; F Alongi
Journal:  Eur J Clin Nutr       Date:  2016-04-13       Impact factor: 4.016

7.  A randomised controlled trial of Caphosol mouthwash in management of radiation-induced mucositis in head and neck cancer.

Authors:  Kee H Wong; Aleksandra Kuciejewska; Mansour T A Sharabiani; Brian Ng-Cheng-Hin; Sonja Hoy; Tara Hurley; Joanna Rydon; Lorna Grove; Ana Santos; Motoko Ryugenji; Shreerang A Bhide; Chris M Nutting; Kevin J Harrington; Kate L Newbold
Journal:  Radiother Oncol       Date:  2016-07-05       Impact factor: 6.280

8.  Assessment of fully-automated atlas-based segmentation of novel oral mucosal surface organ-at-risk.

Authors:  Jamie A Dean; Liam C Welsh; Dualta McQuaid; Kee H Wong; Aleksandar Aleksic; Emma Dunne; Mohammad R Islam; Anushka Patel; Priyanka Patel; Imran Petkar; Iain Phillips; Jackie Sham; Kate L Newbold; Shreerang A Bhide; Kevin J Harrington; Sarah L Gulliford; Christopher M Nutting
Journal:  Radiother Oncol       Date:  2016-03-09       Impact factor: 6.280

9.  Normal tissue complication probability (NTCP) modelling using spatial dose metrics and machine learning methods for severe acute oral mucositis resulting from head and neck radiotherapy.

Authors:  Jamie A Dean; Kee H Wong; Liam C Welsh; Ann-Britt Jones; Ulrike Schick; Kate L Newbold; Shreerang A Bhide; Kevin J Harrington; Christopher M Nutting; Sarah L Gulliford
Journal:  Radiother Oncol       Date:  2016-05-27       Impact factor: 6.280

10.  Dose escalation in advanced floor of the mouth cancer: a pilot study using a combination of IMRT and stereotactic boost.

Authors:  Tomáš Blažek; Zuzana Zděblová Čermáková; Lukáš Knybel; Pavel Hurník; Jan Štembírek; Kamila Resová; Tereza Paračková; Martin Formánek; Jakub Cvek; Renata Soumarová
Journal:  Radiat Oncol       Date:  2021-06-29       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.